Solutions
GB Health
GB Health focuses on building a clinical lab able to deliver actionable results to our partners in the clinic and pharma.
Galatea Bio is a CLIA/CAP accredited lab as such we are able to maintain a clinical chain-of-custody and to deliver to our physicians and partners clinically actionable results. As our Community and Discovery Solutions identify new targets we are able to offer those directly to the community all while maintaining a focus on our best-in-class ancestry tools which help narrow access and health outcomes.
Pharmacogenetic (PGx) testing is for genotyping or sequencing the genes responsible for metabolizing many of the medications prescribed. By focusing on an individual’s genetics we can empower physicians to personalize medications and thereby reduce adverse drug reactions (ADRs). Our initial focus is on CYP2C19 but will expand to other individual, and multiplexed targets as they are validated.
Since we can maintain a full CLIA chain-of-custody through the process we are able to partner with different pharmaceutical companies interested in connecting with a diverse population on clinical studies. Our goal is to provide the right solution for our pharma partners. Studies underway include (but are not limited to):
